Publication

Systematic comparison of plasma EBV DNA, anti-EBV antibodies and miRNA levels for early detection and prognosis of nasopharyngeal carcinoma

Malaysian Nasopharyngeal Carcinoma, Tan, L. P., Tan, G. W., Sivanesan, V. M., Goh, S. L., Ng, X. J., Lim, C. S., Kim, W. R., Mohidin, T. B. B. M., Dali, N. S. M., Ong, S. H., Wong, C. Y., Sawali, H., Yap, Y. Y., Hassan, F., Pua, K. C., Koay, C. E., Ng, C. C. & Khoo, A. S-B., 8-Oct-2019, In : International Journal of Cancer. 12 p.

Research output: Contribution to journalArticleAcademicpeer-review

APA

Malaysian Nasopharyngeal Carcinoma, Tan, L. P., Tan, G. W., Sivanesan, V. M., Goh, S. L., Ng, X. J., ... Khoo, A. S-B. (2019). Systematic comparison of plasma EBV DNA, anti-EBV antibodies and miRNA levels for early detection and prognosis of nasopharyngeal carcinoma. International Journal of Cancer. https://doi.org/10.1002/ijc.32656

Author

Malaysian Nasopharyngeal Carcinoma ; Tan, L. P. ; Tan, G. W. ; Sivanesan, V. M. ; Goh, Siang Ling ; Ng, Xun Jin ; Lim, Chun Shen ; Kim, Wee Ric ; Mohidin, Taznim Begam Binti Mohd ; Dali, Nor Soleha Mohd ; Ong, Siew Hoon ; Wong, Chun Ying ; Sawali, Halimuddin ; Yap, Yoke Yeow ; Hassan, Faridah ; Pua, Kin Choo ; Koay, Cheng Eng ; Ng, Ching Ching ; Khoo, Alan Soo-Beng. / Systematic comparison of plasma EBV DNA, anti-EBV antibodies and miRNA levels for early detection and prognosis of nasopharyngeal carcinoma. In: International Journal of Cancer. 2019.

Harvard

Malaysian Nasopharyngeal Carcinoma, Tan, LP, Tan, GW, Sivanesan, VM, Goh, SL, Ng, XJ, Lim, CS, Kim, WR, Mohidin, TBBM, Dali, NSM, Ong, SH, Wong, CY, Sawali, H, Yap, YY, Hassan, F, Pua, KC, Koay, CE, Ng, CC & Khoo, AS-B 2019, 'Systematic comparison of plasma EBV DNA, anti-EBV antibodies and miRNA levels for early detection and prognosis of nasopharyngeal carcinoma', International Journal of Cancer. https://doi.org/10.1002/ijc.32656

Standard

Systematic comparison of plasma EBV DNA, anti-EBV antibodies and miRNA levels for early detection and prognosis of nasopharyngeal carcinoma. / Malaysian Nasopharyngeal Carcinoma; Tan, L. P.; Tan, G. W.; Sivanesan, V. M.; Goh, Siang Ling; Ng, Xun Jin; Lim, Chun Shen; Kim, Wee Ric; Mohidin, Taznim Begam Binti Mohd; Dali, Nor Soleha Mohd; Ong, Siew Hoon; Wong, Chun Ying; Sawali, Halimuddin; Yap, Yoke Yeow; Hassan, Faridah; Pua, Kin Choo; Koay, Cheng Eng; Ng, Ching Ching; Khoo, Alan Soo-Beng.

In: International Journal of Cancer, 08.10.2019.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

Malaysian Nasopharyngeal Carcinoma, Tan LP, Tan GW, Sivanesan VM, Goh SL, Ng XJ et al. Systematic comparison of plasma EBV DNA, anti-EBV antibodies and miRNA levels for early detection and prognosis of nasopharyngeal carcinoma. International Journal of Cancer. 2019 Oct 8. https://doi.org/10.1002/ijc.32656


BibTeX

@article{8ac7f87e59874eef84270ba76ab10bef,
title = "Systematic comparison of plasma EBV DNA, anti-EBV antibodies and miRNA levels for early detection and prognosis of nasopharyngeal carcinoma",
abstract = "Nasopharyngeal carcinoma (NPC) is originated from the epithelial cells of nasopharynx, Epstein-Barr virus (EBV)-associated and has the highest incidence and mortality rates in Southeast Asia. Late presentation is a common issue and early detection could be the key to reduce the disease burden. Sensitivity of plasma EBV DNA, an established NPC biomarker, for Stage I NPC is controversial. Most newly reported NPC biomarkers have neither been externally validated nor compared to the established ones. This causes difficulty in planning for cost-effective early detection strategies. Our study systematically evaluated six established and four new biomarkers in NPC cases, population controls and hospital controls. We showed that BamHI-W 76 bp remains the most sensitive plasma biomarker, with 96.7{\%} (29/30), 96.7{\%} (58/60) and 97.4{\%} (226/232) sensitivity to detect Stage I, early stage and all NPC, respectively. Its specificity was 94.2{\%} (113/120) against population controls and 90.4{\%} (113/125) against hospital controls. Diagnostic accuracy of BamHI-W 121 bp and ebv-miR-BART7-3p were validated. Hsa-miR-29a-3p and hsa-miR-103a-3p were not, possibly due to lower number of advanced stage NPC cases included in this subset. Decision tree modeling suggested that combination of BamHI-W 76 bp and VCA IgA or EA IgG may increase the specificity or sensitivity to detect NPC. EBNA1 99 bp could identify NPC patients with poor prognosis in early and advanced stage NPC. Our findings provided evidence for improvement in NPC screening strategies, covering considerations of opportunistic screening, combining biomarkers to increase sensitivity or specificity and testing biomarkers from single sampled specimen to avoid logistic problems of resampling.",
keywords = "systematic comparison, biomarkers, early detection, prognosis, Epstein-Barr virus, nasopharyngeal carcinoma, EPSTEIN-BARR-VIRUS, FAMILIAL RISK, RT-QPCR, CANCER, BIOMARKERS, MICRORNAS, SCREEN, IGA",
author = "{Malaysian Nasopharyngeal Carcinoma} and Tan, {L. P.} and Tan, {G. W.} and Sivanesan, {V. M.} and Goh, {Siang Ling} and Ng, {Xun Jin} and Lim, {Chun Shen} and Kim, {Wee Ric} and Mohidin, {Taznim Begam Binti Mohd} and Dali, {Nor Soleha Mohd} and Ong, {Siew Hoon} and Wong, {Chun Ying} and Halimuddin Sawali and Yap, {Yoke Yeow} and Faridah Hassan and Pua, {Kin Choo} and Koay, {Cheng Eng} and Ng, {Ching Ching} and Khoo, {Alan Soo-Beng} and Pua, {K. C.} and S. Subathra and N. Punithavati and Tan, {B. S.} and Ee, {Y. S.} and Ong, {L. M.} and Hamid, {R. A.} and M. Goh and Quah, {J. C. T.} and J. Lim and Yap, {Y. Y.} and Dipak, {B. D.} and R. Deepak and Lau, {F. N.} and P. Kam and Devi, {S. Shri} and Ong, {C. A.} and Lum, {C. L.} and Ahmad, {N. A.} and S. Halimuddin and M. Somasundran and A. Kam and M. Wodjin and Subramaniam, {S. K.} and Tiong, {T. S.} and Tan, {T. Y.} and Sim, {U. H.} and Tharumalingam, {T. W.} and Ng, {C. C.} and S. Hassan and Tan, {L. P.} and Tan, {G. W.}",
year = "2019",
month = "10",
day = "8",
doi = "10.1002/ijc.32656",
language = "English",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley",

}

RIS

TY - JOUR

T1 - Systematic comparison of plasma EBV DNA, anti-EBV antibodies and miRNA levels for early detection and prognosis of nasopharyngeal carcinoma

AU - Malaysian Nasopharyngeal Carcinoma

AU - Tan, L. P.

AU - Tan, G. W.

AU - Sivanesan, V. M.

AU - Goh, Siang Ling

AU - Ng, Xun Jin

AU - Lim, Chun Shen

AU - Kim, Wee Ric

AU - Mohidin, Taznim Begam Binti Mohd

AU - Dali, Nor Soleha Mohd

AU - Ong, Siew Hoon

AU - Wong, Chun Ying

AU - Sawali, Halimuddin

AU - Yap, Yoke Yeow

AU - Hassan, Faridah

AU - Pua, Kin Choo

AU - Koay, Cheng Eng

AU - Ng, Ching Ching

AU - Khoo, Alan Soo-Beng

AU - Pua, K. C.

AU - Subathra, S.

AU - Punithavati, N.

AU - Tan, B. S.

AU - Ee, Y. S.

AU - Ong, L. M.

AU - Hamid, R. A.

AU - Goh, M.

AU - Quah, J. C. T.

AU - Lim, J.

AU - Yap, Y. Y.

AU - Dipak, B. D.

AU - Deepak, R.

AU - Lau, F. N.

AU - Kam, P.

AU - Devi, S. Shri

AU - Ong, C. A.

AU - Lum, C. L.

AU - Ahmad, N. A.

AU - Halimuddin, S.

AU - Somasundran, M.

AU - Kam, A.

AU - Wodjin, M.

AU - Subramaniam, S. K.

AU - Tiong, T. S.

AU - Tan, T. Y.

AU - Sim, U. H.

AU - Tharumalingam, T. W.

AU - Ng, C. C.

AU - Hassan, S.

AU - Tan, L. P.

AU - Tan, G. W.

PY - 2019/10/8

Y1 - 2019/10/8

N2 - Nasopharyngeal carcinoma (NPC) is originated from the epithelial cells of nasopharynx, Epstein-Barr virus (EBV)-associated and has the highest incidence and mortality rates in Southeast Asia. Late presentation is a common issue and early detection could be the key to reduce the disease burden. Sensitivity of plasma EBV DNA, an established NPC biomarker, for Stage I NPC is controversial. Most newly reported NPC biomarkers have neither been externally validated nor compared to the established ones. This causes difficulty in planning for cost-effective early detection strategies. Our study systematically evaluated six established and four new biomarkers in NPC cases, population controls and hospital controls. We showed that BamHI-W 76 bp remains the most sensitive plasma biomarker, with 96.7% (29/30), 96.7% (58/60) and 97.4% (226/232) sensitivity to detect Stage I, early stage and all NPC, respectively. Its specificity was 94.2% (113/120) against population controls and 90.4% (113/125) against hospital controls. Diagnostic accuracy of BamHI-W 121 bp and ebv-miR-BART7-3p were validated. Hsa-miR-29a-3p and hsa-miR-103a-3p were not, possibly due to lower number of advanced stage NPC cases included in this subset. Decision tree modeling suggested that combination of BamHI-W 76 bp and VCA IgA or EA IgG may increase the specificity or sensitivity to detect NPC. EBNA1 99 bp could identify NPC patients with poor prognosis in early and advanced stage NPC. Our findings provided evidence for improvement in NPC screening strategies, covering considerations of opportunistic screening, combining biomarkers to increase sensitivity or specificity and testing biomarkers from single sampled specimen to avoid logistic problems of resampling.

AB - Nasopharyngeal carcinoma (NPC) is originated from the epithelial cells of nasopharynx, Epstein-Barr virus (EBV)-associated and has the highest incidence and mortality rates in Southeast Asia. Late presentation is a common issue and early detection could be the key to reduce the disease burden. Sensitivity of plasma EBV DNA, an established NPC biomarker, for Stage I NPC is controversial. Most newly reported NPC biomarkers have neither been externally validated nor compared to the established ones. This causes difficulty in planning for cost-effective early detection strategies. Our study systematically evaluated six established and four new biomarkers in NPC cases, population controls and hospital controls. We showed that BamHI-W 76 bp remains the most sensitive plasma biomarker, with 96.7% (29/30), 96.7% (58/60) and 97.4% (226/232) sensitivity to detect Stage I, early stage and all NPC, respectively. Its specificity was 94.2% (113/120) against population controls and 90.4% (113/125) against hospital controls. Diagnostic accuracy of BamHI-W 121 bp and ebv-miR-BART7-3p were validated. Hsa-miR-29a-3p and hsa-miR-103a-3p were not, possibly due to lower number of advanced stage NPC cases included in this subset. Decision tree modeling suggested that combination of BamHI-W 76 bp and VCA IgA or EA IgG may increase the specificity or sensitivity to detect NPC. EBNA1 99 bp could identify NPC patients with poor prognosis in early and advanced stage NPC. Our findings provided evidence for improvement in NPC screening strategies, covering considerations of opportunistic screening, combining biomarkers to increase sensitivity or specificity and testing biomarkers from single sampled specimen to avoid logistic problems of resampling.

KW - systematic comparison

KW - biomarkers

KW - early detection

KW - prognosis

KW - Epstein-Barr virus

KW - nasopharyngeal carcinoma

KW - EPSTEIN-BARR-VIRUS

KW - FAMILIAL RISK

KW - RT-QPCR

KW - CANCER

KW - BIOMARKERS

KW - MICRORNAS

KW - SCREEN

KW - IGA

U2 - 10.1002/ijc.32656

DO - 10.1002/ijc.32656

M3 - Article

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

ER -

ID: 99703586